BioCardia Closes Merger With Tiger X Medical

October 24, 2016—BioCardia, Inc. announced completion of its merger with Tiger X Medical, Inc. As part of the merger, Tiger X Medical will change its name to BioCardia, Inc. BioCardia’s current products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio. The CardiAMP and CardiALLO cell therapies are the company’s biotherapeutic product candidates in clinical development.

BioCardia is transitioning from a private company to a publicly traded company through this merger, which is expected to significantly increase its financial resources. Shortly before the merger, BioCardia converted all outstanding convertible promissory notes into shares of common stock, and the combined company has approximately $25 million in cash available, before the payment of fees and expenses.

In addition to supporting operations, these funds will enable BioCardia to advance its pivotal phase 3 CardiAMP cell therapy program for the treatment of heart failure developed after a heart attack.

The combined company will commence trading under the symbol “BCDA” as of the open of market October 26, 2016 on OTC PINK, advised BioCardia.